Pharmacogenetics of chemotherapy-induced nausea and vomiting

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73(3), 249–262 (2013).•• Excellent review providing a contemporary overview of current management of chemotherapy-induced nausea and vomiting (CINV).
  Medline CASGoogle Scholar
• 2 Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr. Oncol. Rep. 15(3), 276–285 (2013).
  Medline CASGoogle Scholar
• 3 Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 222, 385–386 (1969).
  Medline CASGoogle Scholar
• 4 Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305(16), 905–909 (1981).
  Medline CASGoogle Scholar
• 5 Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmacol. 88(3), 497–499 (1986).
  Medline CASGoogle Scholar
• 6 Costall B, Domeney AM, Naylor RJ, Tattersall FD. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25(8), 959–961 (1986).
  Medline CASGoogle Scholar
• 7 Sanger GJ, Andrews PLR. Treatment of nausea and vomiting: gaps in our knowledge. Auton. Neurosci. 129(1–2), 3–16 (2006).
  Medline CASGoogle Scholar
• 8 Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur. J. Pharmacol. 684(1–3), 1–7 (2012).
  Medline CASGoogle Scholar
• 9 Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem. Rev. 109(7), 3158–3199 (2009).
  Medline CASGoogle Scholar
• 10 Adayev T, Ranasinghe B, Banerjee P. Transmembrane signaling in the brain by serotonin, a key regulator of physiology and emotion. Biosci. Rep. 25(5–6), 363–385 (2005).
  Medline CASGoogle Scholar
• 11 Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 375(1–3), 51–60 (1999).
  Medline CASGoogle Scholar
• 12 Ramnath N, Menezes RJ, Loewen G et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 73(5–6), 305–310 (2007).
  Medline CASGoogle Scholar
• 13 Miller AD, Nonaka S, Jakus J. Brain areas essential or non-essential for emesis. Brain Res. 647(2), 255–264 (1994).
  Medline CASGoogle Scholar
• 14 Smith JE, Paton JFR, Andrews PLR. An arterially perfused decerebrate preparation of Suncus murinus (house musk shrew) for the study of emesis and swallowing. Exp. Physiol. 87(5), 563–574 (2002).
  Medline CASGoogle Scholar
• 15 Horn CC, Kimball BA, Wang H et al. Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS ONE 8(4), e60537 (2013).
  Medline CASGoogle Scholar
• 16 Hornby PJ. Central neurocircuitry associated with emesis. Am. J. Med. 111(8), 106–112 (2001).
  Google Scholar
• 17 Horn CC. Why is the neurobiology of nausea and vomiting so important? Appetite 50(2–3), 430–434 (2008).
  MedlineGoogle Scholar
• 18 Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur. J. Pharmacol. 722(1), 55–66 (2014).•• Review on physiological and biological mechanisms of postoperative nausea and vomiting.
  Medline CASGoogle Scholar
• 19 Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann. Oncol. 22(1), 30–38 (2011).
  Medline CASGoogle Scholar
• 20 Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 12(5), 341–347 (2006).
  Medline CASGoogle Scholar
• 21 De Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother. Pharmacol. 56(3), 231–238 (2005).
  Medline CASGoogle Scholar
• 22 Yaakob N, Malone DT, Exintaris B, Irving HR. Heterogeneity amongst 5-HT3 receptor receptor subunits: is this significant? Curr. Mol. Med. 11(1), 57–68 (2011).
  Medline CASGoogle Scholar
• 23 Janicki PK, Vealey R, Liu J, Escajeda J, Postula M, Welker K. Genome-wide Association study using pooled DNA to identify candidate markers mediating susceptibility to postoperative nausea and vomiting. Anesthesiology 115(1), 54–64 (2011).
  MedlineGoogle Scholar
• 24 Janicki PK, Sugino S. Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting. Exp. Brain Res. 232(8), 2613–2625 (2014).• Provides summary of recent genetic research in postoperative nausea and vomiting.
  Medline CASGoogle Scholar
• 25 Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann. Pharmacother. 43(3), 444–452 (2009).
  MedlineGoogle Scholar
• 26 Hromatka BS, Tung JY, Kiefer AK, Do CB, Hinds DA, Eriksson N. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes, and glucose homeostasis. http://biorxiv.org/content/early/2014/02/04/002386.
  Google Scholar
• 27 Huszno J, Budryk M, Kołosza Z, Nowara E. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 85(5), 278–282 (2013).
  Medline CASGoogle Scholar
• 28 Feero WG, Guttmacher AE, Collins FS. Genomic medicine – an updated primer. N. Engl. J. Med. 362(21), 2001–2011 (2010).
  Medline CASGoogle Scholar
• 29 Reavley CM, Golding JF, Cherkas LF, Spector TD, MacGregor AJ. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat. Space. Environ. Med. 77(11), 1148–1152 (2006).
  MedlineGoogle Scholar
• 30 Angst MS, Lazzeroni LC, Phillips NG et al. Aversive and reinforcing opioid effects. Anesthesiology 117(1), 22–37 (2012).
  Medline CASGoogle Scholar
• 31 Tremblay P-B, Kaiser R, Sezer O et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. 21(11), 2147–2155 (2003).
  Medline CASGoogle Scholar
• 32 Meineke C, Tzvetkov MV, Bokelmann K et al. Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenet. Genomics 18(3), 219–230 (2008).
  Medline CASGoogle Scholar
• 33 Fasching P a, Kollmannsberger B, Strissel PL et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J. Cancer Res. Clin. Oncol. 134(10), 1079–1086 (2008).
  Medline CASGoogle Scholar
• 34 Hammer C, Fasching PA, Loehberg CR et al. Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics 11(7), 943–950 (2010).
  CASGoogle Scholar
• 35 Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 12(1), 22–29 (2012).
  Medline CASGoogle Scholar
• 36 Babaoglu MO, Bayar B, Aynacioglu AS et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin. Pharmacol. Ther. 78(6), 619–926 (2005).
  Medline CASGoogle Scholar
• 37 Perwitasari DA, Wessels JAM, van der Straaten RJHM et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J. Clin. Oncol. 41(10), 1168–1176 (2011).
  MedlineGoogle Scholar
• 38 He H, Yin JY, Xu YJ et al. Association of ABCB1 polymorphisms with the efficacy of ondansetron on chemotherapy-induced nausea and vomiting. Clin. Ther. 36(8), 1242–1252.e2 (2014).
  Medline CASGoogle Scholar
• 39 Kaiser R. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol. 20(12), 2805–2811 (2002).
  Medline CASGoogle Scholar
• 40 Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 9(5), 501–504 (2008).
  CASGoogle Scholar
• 41 Niesler B, Frank B, Kapeller J, Rappold G. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310, 101–111 (2003).
  Medline CASGoogle Scholar
• 42 Krzywkowski K, Jensen AA, Connolly CN, Bräuner-Osborne H. Naturally occurring variations in the human 5-HT3A gene profoundly impact 5-HT3 receptor function and expression. Pharmacogenet. Genomics 17(4), 255–266 (2007).
  Medline CASGoogle Scholar
• 43 Kaiser R, Tremblay P. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 14(5), 271–278 (2004).
  Medline CASGoogle Scholar
• 44 Ward MB, Kotasek D, McKinnon RA. Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics 9(8), 1027–1033 (2008).
  CASGoogle Scholar
• 45 Tsuji D, Kim YI, Nakamichi H et al. Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab. Pharmacokinet. 28(4), 299–304 (2013).
  Medline CASGoogle Scholar
• 46 Janicki PK. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med. Sci. Monit. 11(10), RA322–RA328 (2005).
  Medline CASGoogle Scholar
• 47 Candiotti KA, Birnbach DJ, Lubarsky DA et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 102(3), 543–549 (2005).
  Medline CASGoogle Scholar
• 48 Wesmiller SW, Henker RA, Sereika SM et al. The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients. Biol. Res. Nurs. 15(4), 382–389 (2013).
  Medline CASGoogle Scholar
• 49 Hassan BAR, Yusoff ZBM. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac. J. Cancer Prev. 12(1), 185–191 (2011).
  MedlineGoogle Scholar
• 50 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271–1294 (2002).
  Medline CASGoogle Scholar
• 51 Laugsand EA, Fladvad T, Skorpen F et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur. J. Cancer 47(11), 1682–1691 (2011).
  Medline CASGoogle Scholar
• 52 Deenen MJ, Cats A, Beijnen JH, Schellens JHM. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 16(6), 820–834 (2011).
  Medline CASGoogle Scholar
• 53 Han JY, Lim HS, Yoo YK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1), 138–147 (2007).
  MedlineGoogle Scholar
• 54 Lum DWK, Perel P, Hingorani AD, Holmes MV. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS ONE 8(10), e76648 (2013).
  Medline CASGoogle Scholar
• 55 Petros WP, Hopkins PJ, Spruill S et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 23(25), 6117–6125 (2005).
  Medline CASGoogle Scholar
• 56 Ross JR, Rutter D, Welsh K et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5(5), 324–336 (2005).
  Medline CASGoogle Scholar
• 57 Kasai S, Ikeda K. Pharmacogenomics of the human µ-opioid receptor. Pharmacogenomics 12(9), 1305–1320 (2011).
  CASGoogle Scholar
• 58 Klepstad P, Rakvåg TT, Kaasa S et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232–1239 (2004).
  Medline CASGoogle Scholar
• 59 Tan E, Lim ECP, Teo Y, Lim Y, Law H, Sia AT. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol. Pain. 5(6), 32 (2009).
  MedlineGoogle Scholar
• 60 Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73(1), 107–121 (2003).
  Medline CASGoogle Scholar
• 61 Coulbault L, Beaussier M, Verstuyft C et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4), 316–324 (2006).
  Medline CASGoogle Scholar
• 62 Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105(2), 334–337 (2006).
  Medline CASGoogle Scholar
• 63 Chou WY, Yang LC, Lu HF et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7), 787–792 (2006).
  Medline CASGoogle Scholar
• 64 Sia AT, Lim Y, Lim ECP et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3), 520–526 (2008).
  Medline CASGoogle Scholar
• 65 Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146(3), 270–275 (2009).
  Medline CASGoogle Scholar
• 66 Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain. 4(12), 64 (2008).
  MedlineGoogle Scholar
• 67 Fujita K, Ando Y, Yamamoto W et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother. Pharmacol. 65(2), 251–258 (2010).
  Medline CASGoogle Scholar
• 68 Grant VL. Do conditioned taste aversions result from activation of emetic mechanisms? Psychopharmacology (Berlin) 93(4), 405–415 (1987).
  Medline CASGoogle Scholar
• 69 Mitchell D, Laycock JD, Stephens WF. Motion sickness-induced pica in the rat. Am. J. Clin. Nutr. 30(2), 147–150 (1977).
  Medline CASGoogle Scholar
• 70 Takeda N, Hasegawa S, Morita M et al. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find. Exp. Clin. Pharmacol. 17(10), 647–652 (1995).
  Medline CASGoogle Scholar
• 71 Yamamoto K, Ngan MP, Takeda N, Yamatodani A, Rudd JA. Differential activity of drugs to induce emesis and pica behavior in Suncus murinus (house musk shrew) and rats. Physiol. Behav. 83(1), 151–156 (2004).
  Medline CASGoogle Scholar
• 72 Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci. 41(4), 513–518 (1987).
  Medline CASGoogle Scholar
• 73 Darmani NA, Zhao W, Ahmad B. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J. Neural Transm. 106(11–12), 1045–1061 (1999).
  Medline CASGoogle Scholar
• 74 Percie du Sert N, Chu KM, Wai MK, Rudd JA, Andrews PLR. Telemetry in a motion-sickness model implicates the abdominal vagus in motion-induced gastric dysrhythmia. Exp. Physiol. 95(7), 768–773 (2010).
  MedlineGoogle Scholar
• 75 Horn CC, Meyers K, Pak D, Nagy A, Apfel CC, Williams BA. Post-anesthesia vomiting: impact of isoflurane and morphine on ferrets and musk shrews. Physiol. Behav. 106(4), 562–568 (2012).
  Medline CASGoogle Scholar
• 76 Sam TSW, Cheng JTY, Johnston KD et al. Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew). Eur. J. Pharmacol. 472(1–2), 135–145 (2003).
  Medline CASGoogle Scholar
• 77 Beleslin DB, Rezvani AH, Myers RD. Rostral hypothalamus: a new neuroanatomical site of neurochemically-induced emesis in the cat. Brain Res. Bull. 19(2), 239–244 (1987).
  Medline CASGoogle Scholar
• 78 Robinson BW, Mishkin M. Alimentary responses to forebrain stimulation in monkeys. Exp. Brain Res. 4(4), 330–366 (1968).
  Medline CASGoogle Scholar
• 79 Napadow V, Sheehan JD, Kim J et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb. Cortex 23(4), 806–813 (2013).
  MedlineGoogle Scholar
• 80 Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth. Analg. 112(2), 448–453 (2011).
  Medline CASGoogle Scholar
• 81 Söderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol. Biochem. Behav. 69(3–4), 343–350 (2001).
  Medline CASGoogle Scholar
• 82 Suzuki T, Nurrochmad A, Ozaki M et al. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Neuropharmacology 49(8), 1121–1131 (2005).
  Medline CASGoogle Scholar
• 83 Kawai M, Kawahara H, Hirayama S, Yoshimura N, Ida S. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 38(3), 317–323 (2004).
  Medline CASGoogle Scholar
• 84 Phimister EG, Feero WG, Guttmacher AE. Realizing genomic medicine. N. Engl. J. Med. 366(8), 757–759 (2012).
  Medline CASGoogle Scholar
• 85 Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370(25), 2418–2425 (2014).
  MedlineGoogle Scholar
• 86 ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet. Med. 14(8), 759–761 (2012).
  MedlineGoogle Scholar